Baylor Oncology Medical Director Joins Actinium Pharmaceuticals, Inc. (ATNM.OB)’s Iomab-B Scientific Advisory Board
7/8/2014 11:10:02 AM
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of M. Yair Levy, MD of Baylor to its Scientific Advisory Board (SAB) for Iomab™-B. Iomab™-B, the Company’s lead radioimmunotherapy asset, is entering a Phase 3 trial to potentially address the rapid mortality and significant unmet medical need for older patients with acute myeloid leukemia (AML) and well as in other cancer indications.
Help employers find you! Check out all the jobs and post your resume.
comments powered by